Department of Cardiac, Vascular, and Thoracic Surgery, Kepler University Hospital, Linz, Austria.
Department of Cardiac, Vascular, and Thoracic Surgery, Kepler University Hospital, Linz, Austria.
Ann Thorac Surg. 2020 Feb;109(2):526-533. doi: 10.1016/j.athoracsur.2019.06.065. Epub 2019 Aug 10.
Jehovah's Witnesses (JW) refuse allogeneic blood transfusions and therefore pose a unique challenge in case of major surgery. This retrospective study reviewed an experience with JW patients who were undergoing open heart surgery.
By using patient blood management strategies, 35 adult JW patients underwent cardiac surgery at Kepler University Hospital in Linz, Austria between 2008 and 2017. Outcomes were compared with patients who accepted blood transfusions (non-JW patients) by using propensity score matching.
There were no significant differences in clinical and operative data between the groups. Twelve JW patients (34.3%) were pretreated with erythropoietin and iron, with a preoperative increase in mean hemoglobin of 2.0 g/dL. On admission, hemoglobin was 14.1 ± 1.1 g/dL in JW patients, compared with 13.2 ± 2.0 g/dL in non-JW patients (P = .022). The hematocrit in JW patients was higher throughout the hospital stay, even though 51.4% of non-JW patients received allogeneic red blood cell transfusions. The perioperative red blood cell loss was significantly lower in JW patients than in non-JW patients (619 ± 420 mL vs 929 ± 520 mL; P = .010). Major complication rates were not different between the groups. The hemoglobin at discharge was 11.5 ± 1.5 g/dL in JW patients compared with 10.3 ± 1.3 g/dL in non-JW patients (P < .001). In-hospital mortality was 2.9% in each group, and long-term survival was comparable.
By implementing patient blood management, open heart surgery in JW patients can be performed with low morbidity and mortality. Preoperative optimization of hemoglobin and minimization of perioperative blood loss are cornerstones in the prevention of blood loss, anemia, and transfusions.
耶和华见证人(JW)拒绝异体输血,因此在进行大手术时会带来独特的挑战。本回顾性研究分析了在奥地利林茨的开普勒大学医院接受心脏手术的 JW 患者的经验。
通过采用患者血液管理策略,2008 年至 2017 年期间,35 名成年 JW 患者在奥地利林茨的开普勒大学医院接受了心脏手术。使用倾向评分匹配将结果与接受输血的患者(非 JW 患者)进行比较。
两组在临床和手术数据方面无显著差异。12 名 JW 患者(34.3%)接受了促红细胞生成素和铁的预处理,术前平均血红蛋白增加 2.0 g/dL。入院时,JW 患者的血红蛋白为 14.1 ± 1.1 g/dL,而非 JW 患者为 13.2 ± 2.0 g/dL(P =.022)。尽管 51.4%的非 JW 患者接受了异体红细胞输血,但 JW 患者在整个住院期间的血细胞比容更高。JW 患者的围手术期红细胞丢失明显低于非 JW 患者(619 ± 420 mL 比 929 ± 520 mL;P =.010)。两组主要并发症发生率无差异。JW 患者出院时的血红蛋白为 11.5 ± 1.5 g/dL,而非 JW 患者为 10.3 ± 1.3 g/dL(P <.001)。两组的院内死亡率均为 2.9%,长期生存率相当。
通过实施患者血液管理,JW 患者的心脏手术可以在低发病率和死亡率的情况下进行。术前血红蛋白的优化和围手术期失血的最小化是预防失血、贫血和输血的基石。